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We studied eight children who had measles at 6 to 10
months of age during the 1998 Argentine measles outbreak
and in whom subacute sclerosing panencephalitis devel-
oped 4 years later. We report the genetic characterization
of brain tissue–associated measles virus samples from
three patients. Phylogenetic relationships clustered these
viruses with the wild-type D6 genotype isolated during the
1998 outbreak. The children received measles vaccine;
however, vaccinal strains were not found.
M
easles is often incorrectly regarded as a mild disease,
and priority is not given to measles elimination pro-
grams in some countries (1). Nevertheless, substantial
progress has been made in eliminating measles virus from
the Americas through massive vaccination campaigns and
maintaining high measles population immunity over time.
From 1990 to 1996, measles cases declined from 250,000
to 2,109; however, in 1997, measles reemerged in the
Americas, with 70,983 confirmed cases. From the last
Argentine outbreak (July 1997–May 1999), 10,354 con-
firmed measles cases were reported, most of them in
unvaccinated preschool-aged children in the greater
Buenos Aires metropolitan area (2).
Although measles virus (Morbillivirus genus,
Paramyxovirus family) is not highly neurotropic, it can
establish long-term persistent infection in brain cells.
Three different neurologic complications result from inter-
actions of measles virus with neural tissue. Acute postin-
fectious encephalitis, usually appearing 5–14 days after the
rash, is thought to be a virus-induced autoimmune disease.
Measles inclusion–body encephalitis, which occurs in
immunocompromised patients after a latent period of 3–6
months, is believed to be a direct measles virus infection of
neural tissue. The third form, subacute sclerosing panen-
cephalitis (SSPE), manifests 2–10 years after primary
measles infection as a progressive and fatal chronic neu-
rodegenerative disease caused by persistent defective
measles virus in neurons and oligodendrocytes. SSPE
develops with high titers of anti-measles antibodies both in
cerebrospinal fluid (CSF) and serum, which seem unable
to eliminate measles virus from the brain (3). 
Although measles virus is serologically monotypic,
genetic variability has defined eight clades, including 20
genotypes and a putative new genotype that are geograph-
ically and temporally restricted (4). Evidence does not
indicate that wild-type measles virus strains differ in terms
of either pathogenesis or neurovirulence. Measles virus
recovered from patients with SSPE differs from wild-type
viruses in a number of mutations that mainly affect the
matrix, hemagglutinin (H), nucleocapsid (N), and fusion
genes. The matrix accumulates the highest level of muta-
tions in the entire open reading frame; by contrast, the N is
modified in the carboxyl terminus, and the H has biased
hypermutation in a limited region (5,6). Despite the pauci-
ty of studies in molecular epidemiology of SSPE, measles
virus sequences obtained from brain tissues are homolo-
gous to the genotype circulating at the time of primary
exposure to measles virus (7). 
We studied eight children who had measles as infants
during the 1998 measles outbreak in Argentina and in
whom SSPE developed 4 years later. We report the genet-
ic characterization of brain tissue–associated measles virus
from three of these patients.
The Study
Diagnosis of SSPE was based on Dyken’s criteria,
which include progressive cognitive decline and stereotyp-
ical myoclonus, characteristic electroencephalogram
(EEG) changes, raised CSF globulin levels without pleo-
cytosis, raised CSF measles antibody titers, and typical
histopathologic findings in brain biopsy materials (8). 
Antimeasles immunoglobulin (Ig) G antibodies in CSF
and serum samples were assessed by using an automated
qualitative enzyme-linked fluorescent immunoassay
(bioMérieux, Marcy l’Etoile, France) and a quantitative
indirect immunofluorescence test (Bion, Des Plaines, IL).
In three patients, measles virus RNA was isolated from a
punch of white matter obtained in the course of Ommaya
reservoir implantation at SSPE onset. RNA was purified
by the guanidinium-thiocyanate-phenol-chloroform
method, and genetic characterization of measles virus was
performed by sequencing the 450 nt from the carboxyl ter-
minus of nucleoprotein (N) gene and a 377-bp fragment of
the H gene (9). Viral fragments were reverse-transcribed
with omniscript and sensiscript enzymes, and amplified
with Hot Start Taq DNA Polymerase (QIAGEN GmbH,
Hilden, Germany). Purified polymerase chain reaction
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lyzed in an automatic capillary DNA sequencer
(Amersham Biosciences, Piscataway, NJ). Comparisons
were made with reference measles virus strains (4). Amino
acid sequences were inferred. Nonsynonymous versus syn-
onymous mutations (ω) and transitions versus transver-
sions (κ) ratios were calculated. Sequences were aligned
with ClustalX software, while phylogenetic analysis was
performed by distance methods with Phylip software pack-
age v. 3.5c (10,11). Sequences derived from this study
were submitted to GenBank.
Discussion
Clinical, epidemiologic, and laboratory findings of
eight SSPE patients are described in the Table. Mean age
at SSPE onset was 54 months (range 40–75 months), and
the mean lag period was 48 months (range 33–68 months).
Most patients (six of eight) resided in the greater Buenos
Aires metropolitan area, one from the northeastern region
and the other from the northwestern region. All patients
met at least clinical, EEG, and CSF antibody titer criteria
defined by Dyken (8). In particular, patient 4 (at 6 months
of age) had a clinical diagnosis of measles in September
1998 during the outbreak. Six months later, the patient
received Measles Mumps Rubella (MMR) vaccine accord-
ing to the official immunization schedules. For patient 5,
clinical diagnosis of measles was made at 10 months of
age in September 1998 during the outbreak. At that time,
he also had varicella; 2 months later, the patient received
the MMR vaccine. Patient 6 was born in November 1997
and had no previous history of measles infection. She also
received antimeasles vaccine at 6 months of age during the
measles outbreak when the vaccination age was lowered.
Molecular Findings
The 450 nt from the carboxyl terminus of N gene and a
377-bp segment from H gene from three SSPE cases were
analyzed and amino acid sequences were inferred. When
compared to Edmonston strain, not only were a higher
number of mutations found in N gene (36 vs. 19) but also
more replacement changes (18 vs. 12) and a higher κ ratio
(2.1 vs. 1.2) as compared to H gene. However, we com-
pared the ω ratio and found it to be higher for H gene (1.7
vs. 1). Fixed replacements were detected at position 357 in
H protein and at position 467 in N protein. Variability was
detected in both genes. Changes found in SSPE samples
related to D6 genotype, and the consensus sequence from
last Argentine outbreak are summarized in Figure 1.
Distance methods were applied, and the matrix ren-
dered similar results for both analyzed genes. The tree was
built with measles virus genotype reference strains and
Argentine strains previously characterized from 1991 and
1998 outbreaks. Phylogenetic relationships clustered the
three SSPE strains with the wild-type D6 genotype. SSPE
samples were strongly associated with wild-type D6 sam-
ples from the 1998 outbreak, supported by a bootstrap
value of 100 out of 100 pseudoreplicates done. Divergence
from genotype D6 (NJ-1 strain) was <2.2% in the N gene
and <2.4% in the H gene. The unrooted tree for the car-
boxyl terminus of N gene was plotted (Figure 2).
Conclusions
The measles vaccine was included in the regular immu-
nization schedule in Argentina in 1978. Despite vaccina-
tion, several disease outbreaks have occurred (12).
Although we had previously performed a thorough molec-
ular description of acute measles outbreaks, genetic char-
acterization of SSPE has not yet been reported in
Argentina (9). 
SSPE results in widespread destruction of brain tissue,
including both gray and white matter. Infectious virus like-
ly reaches the brain at the time of the original systemic
spread of measles virus, where the virus becomes clonal,
disseminating gradually throughout the nervous system
from the point of entry (13). High levels of antimeasles
antibodies are found both in serum and CSF, and their rel-
ative titers in the two compartments indicate intrathecal
synthesis of immunoglobulins.
Measles virus in SSPE is characterized by a low expres-
sion of viral envelope proteins as a result of mutational
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Table. Clinical, epidemiologic, and laboratory findings for eight pediatric subacute sclerosing panencephalitis (SSPE) patients
a 
Patient   SSPE1  SSPE2  SSPE3  SSPE4  SSPE5  SSPE6  SSPE7  SSPE8 
Date of birth  Jan-98  Feb-98  Jul-98  Mar-98  Nov-97  Nov-97  Sep-96  Nov-97 
Date of measles disease  Sep-98  Sep-98  May-99  Sep-98  Sep-98  N/A
  Jul-97  Jul-98 
Date of SSPE onset  May-01  Dec-01  Feb-02  Jun-02  Aug-02  Sep-02  Jan-03  Feb-03 
Geographic location  GBA
  GBA  NW
  GBA  GBA  GBA  NE
  GBA 
CSF antibody titers  1:1600  1:1600  1:3200  1:3200  1:400  1:400  1:1600  1:400 
Serum antibody titers  >1:3200  >1:3200  1:12800  >1:3200  >1:3200  1:12800  N/A  1:400 
Initial diagnosis  Progressive 
myoclonic 
epilepsy 
Acute 
disseminated 
encephalo-
myelitis 
Progressive 
myoclonic 
epilepsy 
Neuronal 
ceroid 
lipofucsinosis 
Lennox-Gastaut 
syndrome 
Progressive 
myoclonic 
atonic epilepsy 
Chorioretinitis  Ataxia 
aMolecular studies were done for SSPE patients highlighted in bold type. N/A, not available; GBA, greater Buenos Aires metropolitan area; NW, northwestern region from 
Argentina; NE, northeastern region from Argentina; CSF, cerebrospinal fluid. events. Among such proteins, H is an attachment protein
that mediates binding to cells and contributes to cell-to-cell
fusion. The V357I mutation was one of the fixed changes
that we had detected in the 1998 outbreak, but one of the
SSPE cases (SSPE5) had a nonconservative V357S change
at the same position (from hydrophobic to polar without
charge) (9). This finding indicates that this particular posi-
tion may be under strong positive selection supported by a
high ω=1.7 and a low κ=1.2. Although this fragment is a
relatively small portion of the H gene, it contains a major
antigenic surface determinant (aa368–396), which may be
relevant for neurovirulence, as well as three linear epitopes
containing conserved cysteines 381, 386, and 396. SSPE5
presented 5 replacement changes; one shared with SSPE6
(P368R, D374E, K375Q, Q384H, and P397S) (14,15). 
On the other hand, the N protein is more closely linked
to viral protein interactions and thus has less constraints to
vary as demonstrated by a higher κ (2.1) and lower ω (1)
denoting neutral selection. Nevertheless, the B-cell epitope
(aa457–476) showed the conservative L467P change in
SSPE samples as well as in 1998 outbreak samples, differ-
ing from the D6 reference strain (NJ-1) (16). 
Molecular data from the 1998 Argentine outbreak
showed that the virus belonged to the D6 genotype and that
analyzed regions were highly homogeneous and almost
identical to other D6 strains isolated in South America (9).
Accordingly, a single chain of transmission could be
responsible for the spread of the genotype from European
countries to Brazil and then to Argentina (17). The last
Argentine outbreak began in July 1997 in the northeastern
region of the country, bordering on Brazil; had its peak in
greater Buenos Aires metropolitan area in July 1998; and
ended in the northwestern region bordering on Bolivia in
May 1999. For that reason, a displacement in time of acute
measles and SSPE onset can be observed in SSPE3 and
SSPE7. 
Children in whom SSPE developed were born during
the last measles outbreak and reached 6 months of age
when the outbreak was at its peak. They acquired measles
when they were 8 months of age (range 6–10 months), and
SSPE was not detected among patients >1 year of age at
the time of acute infection; however, underdiagnosis is a
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Figure 1. Replacement changes found in N and H genes from sub-
acute sclerosing panencephalitis patients. Comparisons were
made with D6 genotype reference strain (New Jersey, USA/94/1).
Sample Buenos Aires.ARG/21.98 was taken as a consensus
sequence for the 1998 Argentine outbreak (ARG21.98). Numbers
indicate the position in A-nucleoprotein and B-hemagglutinin pro-
tein, respectively. Dots designate the same residue as genotype
D6. Nonsilent changes are represented by single letter amino acid
code. Antigenic sites are underlined.
Figure 2. Phylogenetic relationships of subacute sclerosing panen-
cephalitis (SSPE) strains. The neighbor-joining unrooted tree was
plotted with Treeview 1.5.2. Reference measles virus strains are
described (2). Wild-type (genotype C1 in 1991 and D6 in 1998) as
well as post-vaccinal cases (genotype A) from the last two
Argentine outbreaks were included (GenBank accession no.
AF263841, 43, 44, 46, 52) (7). SSPE strains are highlighted in
bold type (GenBank accession no. AY253332–37)permanent challenge. Time lag between acute and SSPE
onset was approximately 4 years, according to the report-
ed data, but the rate for developing SSPE was higher than
previously described (8). 
Phylogenetic analysis of three SSPE cases from the last
outbreak clustered with D6 genotype that circulated in
Argentina in 1998. Although the original sequence of the
wild-type virus that caused acute infection is unknown, we
have a consensus sequence that summarizes the outbreak;
therefore, we infer that changes may have occurred since
then and contributed to the development of SSPE.
Although all three patients had been immunized according
to the schedule, vaccinal strains were not detected in brain
tissue. These results agree with those recently reported for
SSPE patients in the United Kingdom and Papua, New
Guinea (18,19). Our data show that these three patients had
been infected with wild-type circulating D6 virus before
immunization. This primary measles virus infection in
nonimmunized infants may be the leading cause of the
high rate of SSPE inferred from our data. After brain tis-
sues of deceased adults were randomly autopsied,
Lawrence et al. raised the possibility that brain measles
infection does not invariably lead to neurologic disease
caused by measles virus. Therefore, neurologic disease
mediated by measles virus may depend on the primary
infection age (20). Although the basis for measles-associ-
ated neurologic disease is unclear and more thorough
molecular studies need to be performed, our findings con-
tribute to worldwide efforts in molecular characterization
of SSPE strains and aim to increase awareness among
physicians to improve diagnosis at early stages.
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